Design Synthesis and SAR of Non-peptidic Urotensin II Agonists

Similar documents
Solutions In each case, the chirality center has the R configuration

Structure at the isoelectric point: The predominant form of this tripeptide at ph 1 has a net charge of: (circle one)

TMSCl imidazole DMF. Ph Ph OTMS. Michael reaction. Michael reaction Ph R 3. epoxidation O R

Conformational Analysis

C H E M I S T R Y N A T I O N A L Q U A L I F Y I N G E X A M I N A T I O N SOLUTIONS GUIDE

Diastereomeric resolution directed towards chirality. determination focussing on gas-phase energetics of coordinated. sodium dissociation

O H HO H. !-D-galactopyranose

Amino Acids and Peptides

R or S? oxidation #: hybridization:

Supporting Information

A. Two of the common amino acids are analyzed. Amino acid X and amino acid Y both have an isoionic point in the range of

Chapter 4: Amino Acids

Other Methods for Generating Ions 1. MALDI matrix assisted laser desorption ionization MS 2. Spray ionization techniques 3. Fast atom bombardment 4.

Aromatic Hydrocarbons

A. B. C. D. 2. Which compound does not give a stable Grignard reagent when reacting with Mg metal?

2311A and B Practice Problems to help Prepare for Final from Previous Marder Exams.

Highlights of Schmidt Reaction in the Last Ten Years

1G (bottom) with the phase-transition temperatures in C and associated enthalpy changes (in

Electronic Supplementary Information

Exam I Answer Key: Summer 2006, Semester C

A Plausible Model Correlates Prebiotic Peptide Synthesis with. Primordial Genetic Code

Chiral Brønsted Acid Catalysis

What makes a good graphene-binding peptide? Adsorption of amino acids and peptides at aqueous graphene interfaces: Electronic Supplementary

Development of Small Organic Molecules as Catalysts for Asymmetric

Hour Examination # 3

Supporting Information

Sequential resonance assignments in (small) proteins: homonuclear method 2º structure determination

Proteins: Characteristics and Properties of Amino Acids

Downloaded from:

Aldehydes and Ketones

1. Draw the structure of oxazolone formed upon activation of N-Acetylvaline

Answer Key Evening Exam 2v1

Affects pk a? Derivatization to Amides. Identify unknown. carboxylic acid

Department of Chemistry, Colorado State University, Fort Collins, Colorado University of Colorado Cancer Center, Aurora, Colorado 80045

Chem 316/422 Beauchamp 1 Match the step number in the synthesis with the letter of the reagents listed just below.

Supporting Information

Section Week 3. Junaid Malek, M.D.

FIVE MEMBERED AROMATIC HETEROCYCLES

Copper-Catalyzed Synthesis of Esters from Ketones. Alkyl Group as a Leaving Group.

Practice Synthetic Problems: CHEM 235 Page 2

NH 2. Biochemistry I, Fall Term Sept 9, Lecture 5: Amino Acids & Peptides Assigned reading in Campbell: Chapter

water methanol dimethyl ether Ether can only act as a hydrogen bond acceptor H-bond acceptor O R

CHEM 203. Final Exam December 15, 2010 ANSWERS. This a closed-notes, closed-book exam. You may use your set of molecular models

MEDICINAL CHEMISTRY I EXAM #1

Electronic Supplementary Information

Synthesis of Peptide-Grafted Comb Polypeptides via Polymerisation of NCA-Peptides

CHMI 2227 EL. Biochemistry I. Test January Prof : Eric R. Gauthier, Ph.D.

B O C 4 H 2 O O. NOTE: The reaction proceeds with a carbonium ion stabilized on the C 1 of sugar A.

Total Synthesis of Saxitoxin

Peptide Syntheses. Illustrative Protection: BOC/ t Bu. A. Introduction. do not acid

Rapid Access to Compound Libraries through Flow Technology: Fully Automated Synthesis of a 3-Aminoindolizine Library via Orthogonal Diversification

Compound Number. Synthetic Procedure

Heterocyclic Chemistry - Midterm. May 6 th, Professor Baran Department of Chemistry The Scripps Research Institute

Ramachandran Plot. 4ysz Phi (degrees) Plot statistics

Chem 250 Evening Exam 2

PROCESS FOR THE PREPARATION OF 5-CYANOPHTHALIDE AND INTERMEDIATES USEFUL THEREIN.

Supporting Information

Read more about Pauling and more scientists at: Profiles in Science, The National Library of Medicine, profiles.nlm.nih.gov

Supporting Information

Supporting Text Synthesis of (2 S ,3 S )-2,3-bis(3-bromophenoxy)butane (3). Synthesis of (2 S ,3 S

OH OH OH CH 2 CH 2 C(CH 3 ) 2 (a) CH 3 CHCH 2 CHCH(CH 3 ) 2. (b)

Chapter 18: Carbonyl Compounds II

Heterocyclic Chemistry Midterm Examination. 3 May Professor Baran Department of Chemistry The Scripps Research Institute

Central Dogma. modifications genome transcriptome proteome

"-Amino Acids: Function and Synthesis

Ligand-receptor interactions

ALCOHOLS: Properties & Preparation

PART-I Development of New Synthetic Methodologies Using Heterogeneous Catalysts or Polyethylene Glycol

Chapter 17: Carbonyl Compounds II

Catalytic Reductive Dehydration of Tertiary Amides to Enamines under Hydrosilylation Conditions

Department of Chemistry SUNY/Oneonta. Chem Organic Chemistry II Examination #4 - May 5, 2003 ANSWERS

Packing of Secondary Structures

Enantioselective Organocatalytic Michael Addition of Malonate Esters to Nitro Olefins Using Bifunctional Cinchonine Derivatives

1-What is substitution reaction? 2-What are can Nucleophilic Substitution Reaction? 3- SN1 reaction. 4-SN2 reaction 5- mechanisms of SN1&SN2

NMR study of complexes between low molecular mass inhibitors and the West Nile virus NS2B-NS3 protease

Chiral Bronsted Acids as Catalysts

Supplementary Figure 3 a. Structural comparison between the two determined structures for the IL 23:MA12 complex. The overall RMSD between the two

CHEM J-8 June Complete the following table. Make sure you give the name of the starting material where indicated. REAGENTS/ CONDITIONS

Preparation of Alkyl Halides, R-X. Reaction of alkanes with Cl 2 & Br 2 (F 2 is too reactive, I 2 is unreactive): R + X X 2.

Q.1 Draw structures for all amines of molecular formula C 4 H 11 N. Classify them as primary, secondary or tertiary amines.

Principles of Biochemistry

Loudon Chapter 19 Review: Aldehydes and Ketones CHEM 3331, Jacquie Richardson, Fall Page 1

CHEM J-9 June 2014

Hour Examination # 3

7.012 Problem Set 1. i) What are two main differences between prokaryotic cells and eukaryotic cells?

Secondary Structure. Bioch/BIMS 503 Lecture 2. Structure and Function of Proteins. Further Reading. Φ, Ψ angles alone determine protein structure

-1- HO H O H. β-d-galactopyranose (A) OMe CH 3 I. MeO. Ag 2 O. O Me HNO 3. OAc (CH 3 CO) 2 O. AcO. pyridine. O Ac. NaBH 4 H 2 O. MeOH. dry HCl.

Chapter 5. Nucleophilic aliphatic substitution mechanism. by G.DEEPA

Nickel-Catalyzed Reductive Cross-Electrophile-Coupling Between Aryl and Alkyl Halides

C C H 2. O p-tsoh (catalytic) H 3 O +! O

Novel Water-Soluble Near-Infrared Cyanine Dyes: Synthesis, Spectral Properties, and Use in the Preparation of Internally Quenched Fluorescent Probes

Unraveling the degradation of artificial amide bonds in Nylon oligomer hydrolase: From induced-fit to acylation processes

Biological Macromolecules

20.3 Alkylation of Enolate Anions

CHEM1907/ J-7 June 2003 B CHO. Give the products obtained when D-xylose is treated with the following reagents. [Ag(NH 3 ) 2 ] + / OH solution

an axial "X" is necessary for a succesful E2 reaction and also works better for S N 2

Supplementary Figure 1. Primary protein sequence alignment of engineered AcEZH2_ X,

Supplementary Information

Properties of amino acids in proteins

Mechanism Problem. 1. NaH allyl bromide, THF N H

Transcription:

MEDICIAL CEMISTY Design Synthesis and SA of on-peptidic Urotensin II Agonists C Val Cys Tyr Lys Trp 2 Glu Thr Pro Asp Cys Phe uman urotensin II (S) pec 50 7.49 () pec 50 5.84 FL-104 AC-7954 Fredrik Lehmann 081203

MEDICIAL CEMISTY Where to start? AC7954 identified as the first non-peptidic Agonist for Urotensin II

MEDICIAL CEMISTY The mission: Try to improve the potency and efficacy relative to AC7954 ow? (step 1) different heterocycles different amines various substitution change "spacer" length various substitution

etrosynthetic analysis MEDICIAL CEMISTY Li Li + + + + Br

Synthesis MEDICIAL CEMISTY Br n-buli C 2 S 2 Me 2 90-99% 80-99% Dioxane mw 180 + + o, 6 min TF, rt + 18-78% 95-99% + n-buli 10-75%

SA (selection) MEDICIAL CEMISTY FL66 Compound pec50 Efficacy AC7954 4-5.95 ± 0.12 133 ± 8 FL60 4-F 5.60 ± 0.02 147 ± 40 FL47 4-CF 3 6.05 ± 0.07 109 ± 10 FL52 4-Me 5.01 ± 0.01 51 ± 1 FL56 3-Me 5.33 ± 0.08 135 ± 51 FL54 2-Me 4.97 ± 0.04 33 ± 4 FL62 3-5.59 ± 0.03 105 ± 18 FL66-6.20 ± 0.01 138 ± 21

Combinations? MEDICIAL CEMISTY 1 2 Compound 1 2 pec50 Efficacy AC7954 4-5.95 ± 0.12 133 ± 8 FL97 3,4-Di- 6.18 181 FL98 6,7-DiMe 2-apthyl 6.91 126 FL99 6,7-DiMe 3-Me 5.58 154 FL101 6,7-DiMe 3,5-Di-Me 5.28 163 Lehmann et al. J Bioorg Med Chem, 2005

Small changes can be vital! MEDICIAL CEMISTY AC-7954 pec 50 = 5.95 Inactive!

Stereochemistry? MEDICIAL CEMISTY AC-7954 16 (+) 16 pec 50 = 7.11 (-) 16 pec 50 = 5.78

Summary of SA MEDICIAL CEMISTY naphthyl tolerated methyl good, phenyl too large not necessery for activity can be exhanged for -alkyl chirality important two carbons most favorable substitution forbidden larger rings tolerated but not smaller dimethyl optimal, larger systems deterimental for activity Ph tolerated, Ph or CCPh too sterically demanding substitution pattern important, but difficult to predict

MEDICIAL CEMISTY The mission: Try to improve the potency and efficacy relative to AC7954 ow? (step 2) + pec 50 = 5.95 pec 50 = 5.77

MEDICIAL CEMISTY i 1 ii 3v, w iii iv, v vi 2 4a - e vii 2 viii ix 6a - u S 5a - s 8d, e, v 7a - u i) LA, TF, 91%. ii) -C 2 -X, PS-DIPEA, C 2 2, 48 and 78%. iii) -C, EDC, DMAP, C 2 2, 43-98%. iv) C 3 C, 2 S 4. v) 6M (aq), >99%. vi) -C, Et 3, TF, 29-91%. vii) -C, S 2, Et 3, TF, 42-98% or -C, EDC, DMAP, C 2 2, 60-67%. viii) -S 2 -, Et 3, TF, quant. ix) -C, Et 3, TF, 38-98% Lehmann et al. J Med Chem 2006

SA (selected) MEDICIAL CEMISTY 3v, w 4a - e 5a - e cmpd pec50 Efficacy n 3v 4-MePh A c 2 3w 2-Me-Ph A c 2 4a 2-MePh 5.77 ± 0.01 126 ± 34 2 4b 4-Me-Ph 5.66 ± 0.2 84 ± 28 3 4c 4-CF 3 -Ph 5.76 ± 0.15 47 ± 18 3 4d 4-Ph-Ph 6.28 ± 0.14 53 ± 27 2 4e 2-aphthyl 5.68 ± 0.04 49 ± 28 3 5a 2-MePh 5.45 ± 0.04 175 ± 15 2 5b 4-Me-Ph 5.87 ± 0.2 162 ± 38 5 5c 4-CF 3 -Ph 7.11 ± 0.1 115 ± 14 3 5d 4-Ph-Ph 7.11 ± 0.01 116 ± 11 2 (-) 5d 4-Ph-Ph 5.84 ± 0.1 96 ± 16 5 (+) 5d 4-Ph-Ph 7.49 ± 0.33 116 ± 18 5 5e 2-aphthyl 6.39 ± 0.19 109 ± 18 2

SA (selected) MEDICIAL CEMISTY S 6a - u 7a - u 8d, e, v cmpd pec50 Efficacy n 6a 2-MePh 5.41 ± 0.07 176 ± 28 4 6b 4-Me-Ph 5.78 ± 0.21 170 ± 48 3 6c 4-CF 3 -Ph 6.60 ± 0.13 94 ± 22 3 6d 4-Ph-Ph 6.57 ± 0.12 58 ± 16 3 6e 2-aphthyl 6.28 ± 0.26 89 ± 19 3 7a 2-MePh 5.64 ± 0.15 175 ± 23 4 7b 4-Me-Ph 5.70 ± 0.06 195 ± 31 3 7c 4-CF 3 -Ph 6.93 ± 0.11 105 ± 14 3 7d 4-Ph-Ph 6.84 ± 0.11 91 ± 18 3 7e 2-aphthyl 6.54 ± 0.1 106 ± 21 3 8d 4-Ph-Ph A 3 8e 2-aphthyl A 3 8v 4-MePh 5.19 ± 0.09 74 ± 10 4

r another way MEDICIAL CEMISTY 1 2 + 2 i 2 1 A - C 1-10 {A1 - C10} i) PS-DCC 2 eqv, PS-DMAP 0.2 eqv, C 2 2, rt, 96h, 46-98% Works even in small scale... Cmpd Scale (mg) Yield Purity Scale (mg) Yield Purity {A1} 25 94 100 5 92 100 {A7} 25 83 100 5 97 100 Lehmann et al. Eur J Med Chem 2007

2 2 2 A B C MEDICIAL CEMISTY 1. = 2. = CF 3 3. =Me 4. = 5. = CF 3 6. =Me 7. = 8. = CF 3 9. = Me cmpd A B C 10 Extraction Yield Purity Ion ex Yield Purity Extraction Yield Purity Ion ex Yield Purity Extraction Yield Purity Ion ex Yield Purity 1 92 100 - - 93 100 - - 67 100 - - 2 96 100 - - 98 100 - - 88 100 - - 3 96 100 - - 93 100 - - 79 100 - - 4 92 100 - - 96 100 - - 66 100 - - 5 83 100 - - 78 100 - - 84 100 - - 6 91 100 - - 98 100 - - 94 100 - - 7 87 85 62 100 132 93 86 100 76 100 - - 8 97 100 - - 56 100 - - 200 51 59 100 9 83 97 68 100 87 100 - - 118 88 47 100 10 147 88 46 100 120 75 60 100 102 76 64 100

2 2 2 A B C MEDICIAL CEMISTY 1. = 2. = CF 3 3. = Me 4. = 5. = CF 3 6. =Me 7. = 8. = CF 3 9. = Me 10 cmpd A B C P EC 50 a Efficacy b P EC 50 a Efficacy b P EC 50 a Efficacy b 1 5.73 ± 0.47 76 ± 5 5.38 ± 0.07 83 ± 11 5.76 ± 0.17 121 ± 31 2 6.06 ± 0.23 53 ± 7 5.95 ± 0.03 25 ± 4 6.24 ± 0.06 40 ± 3 3 5.82 ± 0.21 65 ± 18 5.23 ± 0.05 62 ± 5 A c A c 4 5.78 ± 0.10 139 ± 5 5.34 ± 0.14 73 ± 9 6.22 ± 0.20 107 ± 22 5 5.95 ± 0.31 73 ± 10 5.64 ± 0.09 60 ± 6 6.43 ± 0.07 75 ± 1 6 5.53 ± 0.03 101 ± 12 5.27 ± 0.02 67 ± 14 5.85 ± 0.11 113 ± 9 7 6.37 ± 0.12 128 ± 10 5.81 ± 0.07 97 ± 6 6.23 ± 0.18 116 ± 3 8 6.89 ± 0.06 133 ± 3 6.36 ± 0.08 96 ± 1 6.87 ± 0 117 ± 1 9 6.29 ± 0.04 99 ± 4 5.70 ± 0.08 79 ± 14 6.42 ± 0.06 106 ± 16 10 6.40 ± 0.04 124 ± 6 5.51 ± 0.07 131 ± 0 6.34 ± 0.05 115 ± 14

2 2 2 A B C MEDICIAL CEMISTY 1. = 2. = CF 3 3. = Me 4. = 5. = CF 3 6. =Me 7. = 8. = CF 3 9. = Me 10 140 6,7 120 Efficacy 100 80 60 40 Aliphatic Conjugated pec50 6,2 5,7 A B C 20 5,2 5,7 6,2 6,7 pec50 5,2 1 2 3 4 5 6 7 8 9 10 Acid

Determination of the absolute configuration MEDICIAL CEMISTY 2 Ph Me (,S) + Ph Me (,) C20 1 C9 C10 C8 C11 C7 2 C6 C1 1 C2 21 13 2 C14 C13 C12 1 C15 C3 C4 1 C19 C16 C18 C17 2 4-Ph-Ph-C 2 4-Ph-Ph-C C5 2 X-ray structure of the (,)-methoxy phenyl acet amide (S)-FL104 pec 50 7.49 ()-FL104 pec 50 5.84

MEDICIAL CEMISTY Molecular modelling proposed a pharmacophore for UII-agonists A1 6.70 Å A2 A3 10.8 Å 8.4 Å 4.8 Å 4.8 Å

Focus on Mannich reaction App 300 reaction in 2 mmol scale were run in for various time in seven solvents (water, acetic acid, dioxane, TF, DMF, ethanol, and methanol) at three different temperatures. At 150 o C, pressure jumped one bar => release of formaldehyde

Focus on Mannich reaction MEDICIAL CEMISTY Table 3. esults from synthesis of Mannich bases using various secondary amines. + + 180 o C, 300s dioxane Product Yield a Product Yield a 19 Diethylamine 78 21 Thiomorpholine 46 20 Morpholine 44 22 Piperidine 61 a) All yields are LC yields given as averages of at least two experiments

Focus on Mannich reaction MEDICIAL CEMISTY Lehmann et al, Mol Div 2003

Mannich eaction MEDICIAL CEMISTY a) Values for small scale reactions (2 mmol), values within parenthesis refers to large (40 mmol) scale Lehmann et al, Mol Div 2003

Mannich eaction Lehmann et al, Mol Div 2003